CN1653337A - A2超基序亚单位疫苗 - Google Patents

A2超基序亚单位疫苗 Download PDF

Info

Publication number
CN1653337A
CN1653337A CNA028042484A CN02804248A CN1653337A CN 1653337 A CN1653337 A CN 1653337A CN A028042484 A CNA028042484 A CN A028042484A CN 02804248 A CN02804248 A CN 02804248A CN 1653337 A CN1653337 A CN 1653337A
Authority
CN
China
Prior art keywords
peptide
amino acid
hla
antigen
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028042484A
Other languages
English (en)
Chinese (zh)
Inventor
J·悉尼
A·塞特
H·M·格雷
S·索斯伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of CN1653337A publication Critical patent/CN1653337A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA028042484A 2001-01-29 2002-01-29 A2超基序亚单位疫苗 Pending CN1653337A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26496901P 2001-01-29 2001-01-29
US60/264,969 2001-01-29
US09/935,476 US20040096445A1 (en) 1999-06-30 2001-08-22 Subunit vaccines with A2 supermotifs
US09/935,476 2001-08-22

Publications (1)

Publication Number Publication Date
CN1653337A true CN1653337A (zh) 2005-08-10

Family

ID=26950859

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028042484A Pending CN1653337A (zh) 2001-01-29 2002-01-29 A2超基序亚单位疫苗

Country Status (14)

Country Link
US (1) US20040096445A1 (enExample)
EP (1) EP1368659A2 (enExample)
JP (1) JP2005512016A (enExample)
KR (1) KR20040052475A (enExample)
CN (1) CN1653337A (enExample)
AU (1) AU2002243730B2 (enExample)
CA (1) CA2432995C (enExample)
CZ (1) CZ20032054A3 (enExample)
IL (1) IL156660A0 (enExample)
MX (1) MXPA03006581A (enExample)
NZ (1) NZ526860A (enExample)
RU (1) RU2003126447A (enExample)
SK (1) SK9512003A3 (enExample)
WO (1) WO2002061435A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214275A (zh) * 2016-12-01 2019-09-06 南托米克斯有限责任公司 肿瘤抗原性加工和呈递

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
EP1078092B1 (en) * 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370413A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
AU2605501A (en) * 1999-12-21 2001-07-03 Epimmune, Inc. Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214275A (zh) * 2016-12-01 2019-09-06 南托米克斯有限责任公司 肿瘤抗原性加工和呈递
CN110214275B (zh) * 2016-12-01 2022-12-06 南托米克斯有限责任公司 肿瘤抗原性加工和呈递

Also Published As

Publication number Publication date
EP1368659A2 (en) 2003-12-10
CA2432995A1 (en) 2002-08-08
NZ526860A (en) 2007-03-30
KR20040052475A (ko) 2004-06-23
SK9512003A3 (en) 2003-12-02
IL156660A0 (en) 2004-01-04
AU2002243730B2 (en) 2007-07-12
JP2005512016A (ja) 2005-04-28
WO2002061435A3 (en) 2003-07-10
WO2002061435A2 (en) 2002-08-08
US20040096445A1 (en) 2004-05-20
RU2003126447A (ru) 2005-02-27
CA2432995C (en) 2011-07-26
CZ20032054A3 (cs) 2003-12-17
MXPA03006581A (es) 2004-06-25

Similar Documents

Publication Publication Date Title
EP1917970B1 (en) Hla binding peptides and their uses
US9340577B2 (en) HLA binding motifs and peptides and their uses
EP0703783B1 (en) Methods of making immunogenic hla-a2.1 binding peptides
US7252829B1 (en) HLA binding peptides and their uses
JP4210735B2 (ja) Ｈｌａ―ａ２．１結合ペプチド及びその使用
US20020168374A1 (en) Hla binding peptides and their uses
CN1454082A (zh) 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
JP2006512300A (ja) Ｈｌａ結合ペプチド及びその使用
CN1225590A (zh) 对hla分子结合亲和力提高的肽
CN1333873A (zh) Hiv－特异的t－细胞诱导
CN1096032A (zh) 新的活性化合物
CN1437476A (zh) 优化的小基因及其编码的肽
CN1357006A (zh) 由hlaii类分子呈递的mage－a1肽
CN1452634A (zh) Hla结合肽及其用途
CN1653337A (zh) A2超基序亚单位疫苗
EP1089757B1 (en) Hla binding peptides and their uses
US20040157273A1 (en) Subunit vaccines with a2 supermotifs
CN1910284A (zh) 由HLA－A2402－限制的Ep－CAM－特异的CTL识别的表位/肽及其应用
JP2004517609A (ja) Ｈｌａ−ａ２．１結合ペプチドおよびそれらの用途
US20040157780A1 (en) CTL inducing peptides from c-erb2 (HER-2/neu)
JP2004522415A (ja) Ｈｌａ結合ペプチドおよびその使用方法
CN1711025A (zh) 优化的多表位构建体及其应用
CN1233187A (zh) HIVp－17肽片段、含有该片段的组合物及其制造和使用方法
EP1767542B1 (en) HLA-A2.1 binding peptides and their uses
WO2002020053A1 (en) Hla binding peptides and their uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication